Company history

AroCell originates from research made by Prof. Staffan Eriksson, Dr. Ellen He, Prof. Sven Skog, and Prof. Bernhard Tribukait. Below you can read about major milestones made by AroCell towards improved precision monitoring of cancer diseases.


  • AroCell started a collaboration with Tampere University Hospital (TAYS) to evaluate AroCell’s TK 210 ELISA for Thymidine Kinase 1 (TK1) as a prognostic biomarker in subjects with prostate cancer. The aim of the study is to determine the prognostic value of TK1 in newly diagnosed subjects with prostate cancer.
  • The PROMIX study is now viewable by the public online. The study shows that Thymidine kinase 1 can be used for early therapy response in the treatment of breast cancer.
  • AroCell started a collaboration with Dana Farber Cancer Institute to evaluate AroCell TK 210 ELISA on patients treated with CDK4/6 inhibitors. The purpose of the study is to examine the compliance of TK1 content in serum and clinical response to treatment.
  • Several new distributor agreements have been signed for distribution in the United States, China, India, and France. AroCell thus has seven distributors that cover large parts of North America, Asia, and Europe.
  • AroCell started a collaboration with Corgenix INC., that offers an analysis of Thymidine kinase 1 using AroCell TK 210 ELISA in the United States. AroCell TK 210 ELISA kits have been validated and accepted for Thymidine kinase 1 (TK1) measurements in human samples for preclinical and clinical use at Corgenix Laboratory plant in Colorado, USA.
  • The European Patent Office (EPO) granted AroCell a new patent (No. 3083698) entitled “Monoclonal anti-TK1 antibodies”. The patent refers to AroCell’s proprietary technology for the specific and sensitive immunological measurement of Thymidine kinase 1 in serum. More specifically, the monoclonal antibody XPA210-Ar1 is covered by the patent. The patent was published on 10 April 2019.
  • A new study result, titled “The Combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate Prostate cancer from non-cancerous conditions”, with AroCell TK 210 ELISA at Prostate cancer Published.


AroCell signs a non-exclusive license agreement with Roche Diagnostics, one of the world’s largest diagnostic companies focused on cancer. In addition, the company signs a distribution agreements covering S. Korea, Taiwan, and China, as well as France, Switzerland, Morocco, Algeria and Tunisia. Additional capital of 35 MSEK is contributed to the company through an issue of new shares. A study is presented at ISOBM in Hamburg comparing the analytical performance of AroCell TK 210 ELISA to other technologies measuring TK1 in blood samples from hematological patients. AroCell hires Michael Brobjer as CEO and Anders Hultman as CFO.


Abstracts from three clinical studies are presented. The first abstract Quantification of cell loss in breast cancer during neoadjuvant treatment assessed by TK1 concentration in serum is presented at ESMO in Singapore. A second research study relating to the use of TK1 and AroCell TK 210 ELISA for in vitro studies of the efficacy of cancer drugs is presented in Liverpool, UK. A third abstract is presented at the AACR 2017 about the combination of AroCell TK 210 ELISA with prostate health index (PHI) for differentiating prostate cancer from non-cancerous conditions. AroCell signs agreements with distributors in UK, Ireland, and the US.


The company initiates two clinical studies. The first one is the SÖS study in which patients diagnosed with prostate cancer are monitored using TK 210 ELISA. The second study focuses on sarcoma patients who are monitored from diagnosis through treatment and follow-up using AroCell TK 210 ELISA. The patent application covering the monoclonal antibodies is approved by the European Patent Office. The first clinical study using our TK 210 ELISA, A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease, is published in Tumor Biology. AroCell is listed on NASDAQ First North.


AroCell receives €50 000 under the Horizon 2020 program. TK 210 ELISA is CE-marked, and the product is registered by the Competent Authority in Sweden, Läkemedelsverket. AroCell announces its intention to apply for a listing on NASDAQ First North and 52 MSEK is contributed to the company through a fully guaranteed directed share issue.


The patent application filed in 2013 is extended to cover Europe. The product design specifications are changed resulting in improved specificity and sensitivity and benefits to manufacturing. An additional 8,6 MSEK is contributed based on the exercise of options issued earlier, and 21,3 MSEK in a directed share issue.


A new patent application relating to monoclonal antibodies and their use is filed in Sweden. These monoclonal antibodies are used as components in AroCell TK 210 ELISA. An additional 11,2 MSEK of financing is received by the company following the issue of Units (shares and options).


AroCell launches TK 210/hem ELISA For Research Only. Additional financing of 8,5 MSEK is contributed to the company through an issue of Units (shares and options).


AroCell AB is listed on Aktietorget and a share issue generates 6,9 MSEK (before transaction costs) for AroCell.


In 2009, the development of TK 210 ELISA is initiated. In 2010, the use of TK210 ELISA shows promising clinical results for monitoring of hematological malignancies. The patent application relating to monitoring of progression of cancer disease is approved by the European patent office.


Xi Bao Research AB changes name to AroCell AB and the company receives a prize from Venture Cup East for its innovative business plan. The same year, AroCell receives soft financing from Vinnova through EUREKA, the European network for transnational research projects and start-ups. A year later, AroCell’s first immunohistochemistry product designed for detection of TK1 in tissues is made available. An additional patent application is filed in 2008 where a peptide (XPA161) is described as well as the resulting antibodies and their use.


Xi Bao Research AB is incorporated in 2003. The patents are owned by the company and the team’s activities relating to TK1 are carried out under this umbrella. The same year, an additional patent application relating to the prognosis of cancer progression is filed. Ellen He and Sven Skog sell their shares in the company.


AroCell originates from research made by Staffan Eriksson, Ellen He, Sven Skog, and Bernhard Tribukait. Two patent applications are filed in 1995 relating to the use of Thymidine Kinase 1 (TK1), a specific peptide (XPA210™), the corresponding antibodies, and the use of these in cancer diagnostics. The US patent application is approved in 2000 and the European patent covering UK, France, Germany, Italy, and Sweden is approved a year later, in 2001.